Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin57.2%+1.8pp55.4%+0.9pp54.5%+0.6pp53.9%0.0pp53.9%-1.2pp
Operating margin-70.1%+1.4pp-71.5%+5.9pp-77.4%+2.7pp-80.1%-2.2pp-78%-8.5pp
Net margin-60.3%+12.7pp-73%+14.9pp-87.9%+6.1pp-94%+7.6pp-101.6%-17.5pp
Returns
Return on equity-22.7%
Return on invested capital-29.4%
Efficiency
Asset turnover0.3×-0.1×0.4×
Liquidity
Current ratio10.7×+2.0×8.7×-2.0×10.6×-4.0×14.7×-1.2×15.9×+9.6×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Per Share
Book value per share$6.10-14.0%$7.10+5.0%$6.76-2.8%$6.95-31.9%$10.22+126%
Valuation
Market capitalization$708.98M-8.6%$1.34B+55.3%$863.75M+26.7%$681.56M
Price / sales6.4×13.4×+3.6×9.8×+1.0×8.7×
Price / book2.6×4.7×+1.7×2.9×+0.7×2.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Beta Bionics, Inc. Common Stock's profit margins?
Beta Bionics, Inc. Common Stock (BBNX) runs a 57.2% gross margin and a -70.1% operating margin, with a -60.3% net margin.
Where do Beta Bionics, Inc. Common Stock's ratios come from?
Every ratio is computed from Beta Bionics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.